The abstract is read at the publisher; the summary is JClub's.
In 60 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, prereperfusion dapagliflozin (20 mg then 10 mg daily) did not reduce enzymatic infarct size.
- Why it matters: Although sodium-glucose cotransporter-2 inhibitors show cardioprotection in ischemia-reperfusion models, their acute benefit in ST-segment elevation myocardial infarction is uncertain, especially via mitochondrial effects.
- What they did: In a randomized, double-blind, placebo-controlled trial, investigators compared dapagliflozin versus placebo for 12 weeks, using 72-hour area under the curve of high-sensitivity cardiac troponin I as the primary endpoint.
- The result: The adjusted difference in infarct size was -0.89 × 10^6 arbitrary unit (P = 0.47), with only a transient 2-week rise in mitochondrial respiratory capacity and no sustained benefit or significant differences in cardiac magnetic resonance infarct size.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.